Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

FRM F144 - Emerging Molecular Diagnostics for the Evaluation of Melanoma and Borderline Melanocytic Neoplasms for Dermatologists and/or Dermatopathologists

Open admission to eligible categories, no tuition or ticket


Date: Tuesday, March 25

CME Credits: 2.00

Location: Room 705/707

Time: 10:00 AM - 12:00 PM

Director: Pedram Gerami, MD, FAAD

  • Laura K. Ferris, MD, PhD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Discuss alternative non-invasive strategies for the clinical management of pigmented lesions
  • Recognize the strengths and utility of various types of molecular diagnostics for borderline melanocytic neoplasms
  • Recognize new molecular based prognostic tests for melanoma

The session will review several new molecular tests that help in the clinical management of pigmented lesions. This will include a review of tape stripping which uses mRNA from the surface of pigmented lesions to classify as benign or malignant. We will also discuss the utility of FISH and CGH as well some mRNA based strategies to predict prognosis in borderline melanocytic neoplasms such as Spitz tumors. Lastly we will focus on reviewing new molecular based prognostic assays for melanoma such as Castle Biosciences prognostic assay which groups melanomas into a class 1/non-aggressive or class 2/aggressive signature.


Tuesday, March 25
10:00 AMNovel strategies to Improve Clinical Diagnosis and Management of Melanoma / Dr. Ferris
10:45 AMMolecular based strategies for Diagnosis and Prognosis of Melanoma / Dr. Gerami